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Abstract
Background/objectives
Advances in cancer management have resulted in improved survival rates, particularly in
children and young adults. However, treatment may adversely affect reproductive outcomes
among female cancer survivors. The objective of this study was to investigate their risk of
adverse perinatal outcomes compared to the general population.
Design/methods
We performed a population-based analysis, including all female cancer survivors diagnosed
before the age of 40 years between 1981 and 2012. Pregnancy and perinatal complications
were identified through linkage of the Scottish Cancer Registry with hospital discharge rec-
ords based on the Community Health Index (CHI) database. We compared 1,629 female
cancer survivors with a first ever singleton pregnancy after diagnosis, with controls matched
on age, deprivation quintile, and year of cancer diagnosis selected from the general popula-
tion (n = 8,899). Relative risks and 95%-confidence intervals of perinatal risks were calcu-
lated using log-binomial regression.
Results
Survivors were more likely to give birth before 37 weeks of gestation (relative risk (RR])
1.32, 95%-CI 1.10–1.59), but did not show an increased risk of low birth weight (<2.5kg: RR
1.15, 95%-CI 0.94–1.39), and were less likely to give birth to offspring small for gestational
age (RR 0.81, 95%-CI 0.68–0.98). Operative delivery and postpartum haemorrhage were
more common but approached rates in controls with more recent diagnosis. The risk of con-
genital abnormalities was not increased (RR 1.01, 95%-CI 0.85–1.20).
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Conclusion
Cancer survivors have an increased risk of premature delivery and postpartum haemorrhage,
but their offspring are not at increased risk for low birth weight or congenital abnormalities. In
recent decades there has been a normalisation of delivery method in cancer survivors, never-
theless careful management remains appropriate particularly for those diagnosed in childhood.
Introduction
Advances in cancer management have resulted in improved five year survival rates in children
and young adults [1]. The impact on later health of survivors is high: quality of life is consis-
tently lower in breast cancer survivors as compared to women without a history of cancer [2,
3], 75% of cancer survivors develop at least one health problem [4], and childhood cancer sur-
vivors are 8.2 times more likely to have a severe or life-threatening chronic condition such as
premature gonadal failure in comparison to their peers [5, 6]. Fertility is an important issue for
survivors [7, 8] but concerns about risks of pregnancy can be a reason to avoid pregnancy [9].
Female survivors of cancer who successfully conceived have been identified to be at risk of
premature delivery [10–14] and their offspring have in some studies, but not consistently, been
found to be at increased risk of low birth weight [10–13, 15, 16]. Reassuringly, there does not
appear to be an increased risk of congenital abnormalities in their offspring [16–22]. Two small
studies, one including childhood cancer survivors [23] and one including survivors of cervical
cancer treated with cervical conisation [14], did not identify survivors to be at additional risk of
caesarean section as mode of delivery. However, in two large population based studies, a British
cohort of childhood cancer survivors [10] and a Finnish cohort of survivors of childhood and
young adult cancer diagnosed between 0–35 years [24], the rate of elective caesarean section
was increased, while the risk of emergency caesarean section was not increased.
The adverse impact of cancer treatment on pregnancy outcomes has to date been investi-
gated in selected patient groups based on diagnosis or age at diagnosis. Reports from the Brit-
ish Childhood Cancer Survivors Study (BCCSS) and the US Childhood Cancer Survivors
Study (CCSS) are confined to long-term survivors diagnosed with cancer between 0–14 years
from 1940–1991 in Britain (BCCSS) and 0–21 years at diagnosis from 1970–1986 in the 25 par-
ticipating institutions in Canada and the United States (CCSS) [10, 15, 25, 26]. Other studies
excluded the youngest age group and included adolescent and young adult cancer survivors
diagnosed with cancer between ages such as 15–39 [11, 20] or 16–45 years [21]. Studies focus-
ing on young adults surviving breast cancer [12, 27], colorectal cancer [28] or cervical cancer
[14] have provided insight into perinatal risks in these specific patient groups but their results
cannot with confidence be extrapolated to survivors of other types of cancer. Inference of con-
clusions to current cohorts is limited by the relatively old cohorts often reported. Survivors in
both the CCSS and BCSS were diagnosed several decades ago [10, 15, 25, 26], and the treat-
ment regimens administered may no longer be used [8]. Furthermore, reports based on self-
reported questionnaires [13, 14, 29, 30] or from specialist paediatric oncology centres such as
the CCSS, may under- or overestimate the prevalence of certain events as a result of recall or
selection bias, especially when the event was a substantial time ago. Population registries are
less prone to recall bias and offer the opportunity to study pregnancy outcomes and perinatal
risks at a population level in comparison to the background risk. The objective of this study is
to evaluate the perinatal risks among all female survivors from cancer in Scotland diagnosed
before 40 years of age in the time period 1981–2012.
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Materials and methods
The Scottish Cancer Registry contains data on cancer diagnoses for all patients in Scotland. All
females diagnosed with cancer between 1981 and 2012 before the age of 40 years were identi-
fied. They were linked to national general and maternity hospital discharge records to ascer-
tain subsequent first pregnancies leading to delivery of a live, singleton infant up until the end
of 2014, using the Community Health Index (CHI) number, a unique identifying number
from the CHI database, a population-based register of all patients registered to receive care
from the NHS in Scotland. Deliveries occurring less than 6 months following the date of cancer
diagnosis were excluded. Population-weighted fifths of Carstairs deprivation scores were
assigned to each individual based on census-derived Carstairs scores from 1991 and 2001 for
the periods of diagnosis 1981–1995 and 1996–2012, respectively [31]. A comparison group
was created from the general population, using the CHI database. For every cancer survivor,
three controls were selected matched on age at date of cancer diagnosis/matching and depriva-
tion quintile. Controls had no pregnancies before the date of matching: subsequent first preg-
nancies leading to delivery of a live singleton infant (at least 6 months after the date of
matching) were identified for comparison to deliveries among cancer cases. Only live singleton
births in controls and cancer survivors were included in the analyses.
Maternal outcomes that were evaluated included antenatal haemorrhage, postpartum
haemorrhage, and mode of delivery: spontaneous vaginal, assisted vaginal, elective caesarean
section or emergency caesarean section. Infant outcomes included birthweight, gestational
age, small for gestational age (SGA), admission to neonatal unit and congenital abnormalities
(ICD codes in S1 Table). Low birthweight was defined as a birthweight <2500 grams, prema-
ture delivery as delivery before 37 weeks of gestation and SGA as<10th centile birthweight for
gestational age and gender based on the UK90-WHO growth reference [32].
Age at diagnosis of cancer (and its treatment) may affect perinatal risks, therefore data were
stratified based on age at diagnosis; 0–14 years; 15–24 years; 25–29 years; 30–34 years; 35–39
years. To evaluate possible effects of socio-economic circumstances, data were stratified based on
deprivation fifth. Finally, to investigate possible differences in risk patterns over time, data were
stratified into 7-year periods of diagnosis: 1981–1988; 1989–1996; 1997–2004; 2005–2012. P-val-
ues for the observed difference were calculated from the two-sample z-test for comparing propor-
tions or t-test for comparing means, and log-binomial regression was employed to calculated risk
ratios and 95% confidence intervals. Statistical analyses were conducted in Stata version 14 MP.
The study was approved by the Privacy Advisory Committee of the National Health Service
(NHS) National Services Scotland (NSS)–study reference number XRB13215.
Results
A total of 10,271 nulliparous women diagnosed with cancer before 40 years of age between
1981 and 2012 were identified, of whom 1,629 subsequently delivered a first singleton live
birth by end 2014. Of 30,811 nulliparous matched control women, 8,899 delivered a first sin-
gleton live birth. The 1,629 survivors and the 8,899 matched control women formed the final
cohorts. Half of the cancer survivor cohort had been diagnosed before 25 years of age (48%).
The most common malignancies were melanoma and non-melanoma skin cancers (36.7%)
followed by Hodgkin lymphoma (11.0%) (Table 1).
Cancer survivors were slightly older at first pregnancy than controls (30.1 vs 28.5 years
p<0.001) (Table 1); body mass index (BMI) at booking was similar with 25.5 kg/m2, although
there were substantial missing data (59.9% in survivors and 72.1% in controls). Smoking was
less prevalent in survivors, especially in those diagnosed during childhood (15.1% vs 28.0%,
p<0.001) and adolescence (11.0% vs 15.5%, p = 0.005) (Table 1).
Perinatal risks in female cancer survivors
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Survivors were more likely to deliver prematurely (RR 1.32, 95% CI 1.10–1.59), but did not
show a significantly increased risk of low birthweight (RR 1.15, 95% CI 0.94–1.39) (Table 2).
Offspring of cancer survivors were less likely to be small for gestational age (RR 0.82, 95% CI
0.68–0.98) than offspring from the general population (Table 3). This difference in gestational
adjusted birthweight was not observed in the more recently diagnosed groups or in more
deprived quintiles (S2 Table).
A spontaneous vaginal delivery was less common in survivors than in the general popula-
tion (RR 0.72, 95% CI 0.65–0.79) (Table 4). Elective caesarean section was more common in
cancer survivors than in the general population (RR 1.59, 95% CI 1.35–1.88), as was emer-
gency caesarean section (RR 1.20, 95% CI 1.08–1.34)). The risk of an elective caesarean sec-
tion was most increased in women who had been diagnosed aged 0–14 years (RR 3.15, 95%
CI 2.04–4.88). There were marked changes by period of diagnosis, with the frequency of
operative delivery converging with controls with more recent diagnosis (Fig 1, panel B and
E). This was most strikingly seen in the elective caesarean section rate, which declined in
cancer survivors while increasing in controls (Fig 1, panel B). In those diagnosed between
1981–1988 the elective caesarean section rates were 10.4% vs 3.5% in controls (p<0.001),
while the rates for those diagnosed in 2005–2012 were 7.2% vs 6.8% (p = 0.8) (S3 Table).
While in both the survivor and control group the emergency caesarean section rates rose by
period of diagnosis, the absolute difference in prevalence remained constant (Fig 1, panel
E). Survivors in the lowest and highest quintile of deprivation were more likely to have an
emergency caesarean section than their matched peers, while there was no difference in risk
for survivors in the middle quintiles (Fig 1, panel F).
There was no marked increased risk of antepartum haemorrhage (RR 1.13, 95% CI
0.86–1.50) for the cancer survivors. Postpartum haemorrhage occurred more often in cancer
survivors (RR 1.42, 95% CI 1.29–1.55) (Table 4). The prevalence of postpartum haemorrhage
increased in the control general population over time from 9.3% to 33.1%, while in the cancer
Table 1. Diagnostic characteristics of 1,669 included female cancer survivors with a subsequent live singleton first
ever birth after diagnosis.
Number % of included cohort
Type of first cancer
Colorectal 22 1.4
Liver 5 0.3
Bone 27 1.7
Skin (melanoma and NMSC) 598 36.7
Connective and soft tissue 30 1.8
Breast 112 6.9
Cervix uteri 118 7.2
Ovary 105 6.4
Kidney 20 1.2
Eye 8 0.5
Brain, CNS 66 4.1
Thyroid 128 7.9
Hodgkin lymphoma 179 11.0
Non-Hodgkin lymphoma 48 2.9
Leukaemia 81 5.0
Other 82 5.0
NMSC = non-melanoma skin cancers; CNS = central nervous system
https://doi.org/10.1371/journal.pone.0202805.t001
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survivors the prevalence increased from 15.8% to 38.3% over time with the prevalence of post-
partum haemorrhage being similar to the control general population for later treated cohorts.
(S4 Table). The risk of postpartum haemorrhage was most increased in women who had been
diagnosed aged 0–14 years (RR 1.62, 95% CI 1.23–2.13), while no increased risk was observed in
women diagnosed between 35–39 years (RR 1.30, 95% CI 0.92–1.83).
Offspring of cancer survivors were equally likely to be admitted to a neonatal unit (RR 1.03,
95% CI 0.90–1.19) and showed no increased risk of congenital abnormalities (RR 1.01, 95% CI
0.85–1.20) (Table 3).
Table 2. Differences in lifestyle factors between female survivors of cancer and a matched control group.
Live singleton births (n) Mean age at 1st pregnancy (years) Smoking during pregnancy (%)
controls survivors controls survivors p-value1 controls survivors p-value2
yes missing yes missing
Total 8,899 1,629 28.5 30.1 <0.001 13.7 30.9 10.2 18.0 <0.001
Age-group at onset of cancer/match (years)
0–14 1,292 186 21.2 23.5 <0.001 2.8 16.8 15.1 5.4 <0.001
15–24 2,849 588 24.9 27.2 <0.001 15.5 37.7 11.0 22.4 0.005
25–29 2,367 457 30.0 31.3 <0.001 8.7 33.9 9.2 19.7 0.759
30–34 1,781 306 34.2 35.2 <0.001 8.4 29.8 6.9 15.0 0.376
35–39 610 92 38.4 38.7 0.204 9.2 21.3 10.9 17.4 0.605
Period of diagnosis of cancer/match
1981–1988 2,700 336 26.3 28.3 <0.001 8.1 71.7 7.1 53.9 0.543
1989–1996 2,690 453 27.9 29.1 <0.001 19.5 19.6 11.5 9.1 <0.001
1997–2004 2,063 480 30.2 31.0 0.010 16.3 8.6 12.7 10.2 0.051
2005–2012 1,446 360 31.3 31.6 0.280 9.5 7.7 8.0 6.4 0.376
Deprivation fifth
1 –Least deprived 1,833 328 30.2 31.4 <0.001 7.8 30.6 5.8 14.0 0.199
2 1,684 315 28.8 30.8 <0.001 11.3 30.4 8.3 15.6 0.112
3 1,808 320 28.0 29.9 <0.001 14.4 30.3 8.4 20.0 0.004
4 1,880 356 28.2 29.5 <0.001 15.9 30.5 12.9 18.8 0.153
5 –Most deprived 1,694 310 27.1 28.8 <0.001 19.2 33.0 15.4 21.9 0.118
Female cancer survivors compared to a control group matched on age, diagnosis date and deprivation quintile.
1p-value obtained from t-test.
2p-value obtained from z-test.
https://doi.org/10.1371/journal.pone.0202805.t002
Table 3. Relative risk of perinatal outcomes among female survivors of cancer.
Controls
n (%)
Survivors
n (%)
RR LCI UCI
Premature birth 548 (6.2%) 113 (8.2%) 1.32 1.10 1.59
Low birthweight 548 (6.2%) 115 (7.1%) 1.15 0.94 1.39
Small for gestational age 811 (9.2%) 121 (7.5%) 0.82 0.68 0.98
Admission to neonatal unit 1,090 (12.2%) 207 (12.7%) 1.03 0.90 1.19
Congenital abnormalities 8,746 (8.4%) 1,593 (9.5%) 1.01 0.85 1.20
Relative risks as compared to a control group matched on age, diagnosis date and deprivation quintile. RR = relative risk; LCI = lower confidence interval; UCI = upper
confidence interval. Low birthweight is defined as <2.5 kg; Premature birth is defined as before 37 weeks of gestation; Small for gestational age is defined as under 10th
centile for gestational age.
https://doi.org/10.1371/journal.pone.0202805.t003
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Discussion
Main findings
This population-based study compared the frequency of adverse perinatal outcomes in cancer
survivors diagnosed in Scotland before 40 years of age between 1981–2012 and non-cancer con-
trols matched from the general population. Survivors were more at risk of a preterm delivery but
their offspring were not at increased risk of low birthweight and had a decreased risk of SGA.
Elective caesarean section was more common in cancer survivors as was emergency caesarean
section, but there were marked changes by period of diagnosis, with the frequency of both elec-
tive and emergency caesarean section converging with controls among those with a more recent
diagnosis. Similar findings of increased but converging risk were found for postpartum haemor-
rhage. The risk of congenital abnormalities in offspring of cancer survivors was not increased.
Strengths and limitations
The major strengths of this study include the population-based approach using national
registry data, which allowed evaluation of all first singleton pregnancy outcomes in female
survivors from cancer, diagnosed at an age under 40 years. A large age matched non-cancer
control group was identified from the general population. Pregnancy outcomes were accu-
rately recorded and free of recall bias, but this study lacks cancer treatment information
including radiotherapy to the abdomen and pelvis as this is not routinely collected in the
databases used for this study. We report on the perinatal risks of female survivors from all
cancers, which results in a heterogeneous cohort with regard to their diagnosis and treat-
ment. The most common malignancies were melanoma and non-melanoma skin cancers
Table 4. Relative risk of vaginal delivery and haemorrhage among female survivors of cancer.
Spontaneous vaginal Assisted vaginal or breech Antepartum haemorrhage Postpartum haemorrhage
RR LCI UCI RR LCI UCI RR LCI UCI RR LCI UCI
Total 0.72 0.65 0.79 1.14 1.00 1.29 1.13 0.86 1.50 1.42 1.29 1.55
Age-group at onset of cancer (years)
0–14 0.63 0.47 0.83 1.25 0.87 1.79 0.55 0.24 1.24 1.62 1.23 2.13
15–24 0.72 0.61 0.84 1.11 0.89 1.39 1.31 0.81 2.13 1.28 1.08 1.53
25–29 0.74 0.62 0.89 1.12 0.88 1.41 1.47 0.86 2.49 1.65 1.40 1.96
30–34 0.65 0.52 0.82 1.25 0.94 1.65 1.35 0.69 2.66 1.33 1.09 1.61
35–39 0.87 0.58 1.32 0.98 0.56 1.70 1.21 0.43 3.42 1.30 0.92 1.83
Period of diagnosis of cancer
1981–1988 0.56 0.45 0.69 1.07 0.76 1.48 0.73 0.23 2.37 1.70 1.29 2.23
1989–1996 0.72 0.60 0.87 1.09 0.82 1.45 0.87 0.50 1.50 1.31 1.07 1.61
1997–2004 0.88 0.74 1.04 1.04 0.83 1.29 0.91 0.57 1.47 1.24 1.06 1.45
2005–2012 0.89 0.74 1.08 1.04 0.84 1.30 1.54 0.93 2.55 1.16 1.00 1.35
Deprivation fifth
1 –Least deprived 0.65 0.53 0.80 1.10 0.84 1.45 1.40 0.79 2.48 1.62 1.36 1.93
2 0.74 0.60 0.92 1.13 0.84 1.50 0.85 0.39 1.87 1.34 1.08 1.67
3 0.76 0.61 0.94 1.07 0.79 1.44 1.34 0.74 2.42 1.30 1.03 1.64
4 0.80 0.65 0.97 1.11 0.85 1.46 0.81 0.40 1.61 1.45 1.18 1.78
5 –Most deprived 0.65 0.52 0.80 1.33 1.00 1.76 1.25 0.71 2.21 1.33 1.06 1.67
Relative risks as compared to a control group matched on age, diagnosis date and deprivation quintile. RR = relative risk; LCI = lower confidence interval; UCI = upper
confidence interval.
https://doi.org/10.1371/journal.pone.0202805.t004
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which are more commonly treated with local therapy with lesser likelihood to impact future
perinatal risks. Although all presented relative risks are compared to an age and period
matched control group, the follow-up for patients diagnosed in the most recent period of
diagnosis is still relatively short, especially for childhood cancer survivors. This may have
influenced the observed trends.
Fig 1. Likelihood of caesarean section in female cancer survivors compared to a matched control group. Panels A,
B and C: difference of likelihood on elective caesarean section in female cancer survivors as compared to a matched
control group, stratified by age-group at onset of cancer (A), period of diagnosis of cancer (B), and deprivation fifth
(C). Panels D, E and F: difference of likelihood on emergency caesarean section by age-group at onset of cancer (D),
period of diagnosis of cancer (E), and deprivation fifth (F). Significant differences (p-value< 0.05) between female
survivors of cancer and controls are depicted with  per stratified group. Blue bars depict the control group, red bars
the cancer survivors.
https://doi.org/10.1371/journal.pone.0202805.g001
Perinatal risks in female cancer survivors
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Interpretation
Cancer survivors achieve fewer pregnancies in comparison to the general population, with an
overall reduction in likelihood of pregnancy after diagnosis of 38% [33]. Concerns about risks
of pregnancy are sufficient reason to avoid pregnancy for some survivors [9]. Overall, our
results are reassuring to cancer survivors who wish to become pregnant. We observed no
increased risk of congenital abnormalities, which is consistent with previous studies of risk of
congenital malformations in offspring of cancer survivors, which also found no an associations
with radiotherapy or chemotherapy treatment [16–22, 34]. Our results of increased risk of pre-
mature delivery among cancer survivors agree with previously reported studies [10–14]. This
has been particularly linked to radiotherapy to fields which include the uterus, particularly in
pre-pubertal girls [35], which can lead to reduced uterine volume and elasticity [36, 37]. In
addition, uterine vascularisation may be impaired, with potential detrimental consequences
for fetal-placental blood flow causing fetal growth restrictions. Our results of no increased risk
of low birthweight are consistent with earlier findings in cohorts with survivors from cancer at
a young [10, 13] and adult [38] age, although in the BCCSS cohort there was an increased risk
in the subgroup that received radiation to a field that included the abdomen [10]. Other
reports in cohorts with women diagnosed at a young age however, did show an increased risk
of low birthweight [16], as did cohorts of women surviving breast cancer [12] and women
diagnosed aged 15–39 years [11]. Maternal smoking is a well-recognised risk factor for low
birthweight [39] and having a small for gestational age baby [40]. In our study, cancer survi-
vors were less likely to smoke during pregnancy than the control general population, especially
those diagnosed in childhood and adolescence. As the prevalence of smoking decreased in the
general population in later periods, the differences between cancer survivors and the control
general population converged. This may suggest that cancer survivors were more aware of the
harmful risks of smoking than the control general population and more inclined to stop or not
to start smoking. This supports the value of ongoing health surveillance in this group [41]. The
z-score of mean birthweight also converged by period of diagnosis, illustrating that offspring
of cancer survivors diagnosed in the eighties and nineties had a higher birthweight than their
control peers, a difference that diminished in the offspring of survivors diagnosed after 1997.
The lower prevalence of smoking during pregnancy in cancer survivors in our study popula-
tion may have in part counteracted the negative effects that treatment strategies such as uterine
radiation have on uterine elasticity. Their earlier adoption of a healthier lifestyle may have
been beneficial to the risk of delivery of offspring that were small for gestational age. Unfortu-
nately, information on smoking during pregnancy was missing in a substantial proportion of
the cancer survivors, and in an even larger proportion of the control general population. These
non-randomly missing data prohibited adjustment for this possible confounder, as excluding
those with missing data from the analysis may lead to biased results [42]. Offspring of the least
deprived survivors also had slightly higher birthweights than their matched controls.
Previous studies have indicated that cancer survivors are at increased risk of postpartum
haemorrhage, but only after abdominal radiation [10, 23] although other studies have reported
no increased risk [20, 24, 43]. We show a higher risk of postpartum haemorrhage in cancer
survivors overall, but as the incidence of postpartum haemorrhage has increased more rapidly
in the control general population, the difference has diminished in the most recent decade. It
is possible that better recording of haemorrhage in routine records (reporting bias), as a result
of intensified surveillance, may have played a role in the higher reported incidence of postpar-
tum haemorrhage in cancer survivors.
A lower threshold for intervention may at least in part explain the higher incidence of both
emergency and elective caesarean section in the cancer survivors, although rates of elective
Perinatal risks in female cancer survivors
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section in particular converged with controls by period of diagnosis. The rate of emergency
caesarean section rose by period of diagnosis in both the survivor and control groups, and
there was no significant difference in risk for any single period of diagnosis. The over three-
fold increased risk of an elective caesarean section in the women diagnosed aged 0–14 is sub-
stantially larger than the impact observed (RR 1.38 in those not treated with radiotherapy and
RR 1.46 in those treated with abdominal radiotherapy) in the BCCSS [10]. In that study 40% of
survivors were diagnosed in the most recent time period included (1985–1991), with preg-
nancy outcomes between 1997 and 2012, thus the pregnancy outcomes may be more compara-
ble to the more recently diagnosed (and more recently pregnant) cohorts in the present data.
Inequalities by deprivation were found in the prevalence of operative delivery, where only
the most and least deprived show an increased risk of emergency caesarean section, whereas
survivors in all deprivation quintiles were at increased risk of elective caesarean section. Depri-
vation is known to be a major factor in increasing health inequalities [44]. It is possible that
survivors from the most deprived group may experience greater medical intervention in their
obstetric care due to the presence of more co-morbidities whereas less deprived survivors may
be more empowered to influence their obstetric care. However these differences require spe-
cific investigation to confirm and determine their basis.
As with the normalized risk of postpartum haemorrhage over time, the impact of a cancer
diagnosis on the risk of an operative delivery also diminished in the later periods, resulting in
equal risks of all modes of delivery for those diagnosed in the most recent cohort. The reduced
impact of a cancer diagnosis on the risk of an intervention during delivery may be a result of
better targeted treatment strategies, and of a reduction of therapeutic exposures known to be
associated with organ toxicity, e.g. radiotherapy in Hodgkin lymphoma [45]. This observation
is also in line with decreased late mortality among survivors of childhood cancer as a result of
reduced radiotherapy and chemotherapy exposure [46].
Conclusion
Cancer survivors are at increased risk of premature delivery and postpartum haemorrhage, but
not of small for gestational age or congenital abnormalities when compared to a non-cancer
control population. It is reassuring that the impact of a cancer diagnosis on postpartum haem-
orrhage and mode of delivery has been greatly reduced in most recently diagnosed cohorts of
survivors, although heightened alertness and careful management in cancer survivors remains
appropriate.
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